Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) saw strong trading volume on Monday . Negative Sentiment: Lantheus suspended its previously issued FY 2026 guidance because of the pending transaction, increasing uncertainty around near-term operating performance and limiting visibility for standalone valuation. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a research note on Wednesday, July 29th. Lantheus Price PerformanceThe company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. Lantheus Company Profile(Get Free Report)Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals.